[go: up one dir, main page]

PE20010490A1 - MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA - Google Patents

MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA

Info

Publication number
PE20010490A1
PE20010490A1 PE2000000804A PE0008042000A PE20010490A1 PE 20010490 A1 PE20010490 A1 PE 20010490A1 PE 2000000804 A PE2000000804 A PE 2000000804A PE 0008042000 A PE0008042000 A PE 0008042000A PE 20010490 A1 PE20010490 A1 PE 20010490A1
Authority
PE
Peru
Prior art keywords
mofetile
mycophenolate
ifn
peg
alpha
Prior art date
Application number
PE2000000804A
Other languages
Spanish (es)
Inventor
Friederike Zahm
Stephen Christopher Pappas
Mary Catherine Graves
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010490A1 publication Critical patent/PE20010490A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL USO DE INTERFERON ALFA 2A, UTILIZANDOSE DE 3-6 MILLONES DE UI ADMINISTRADAS TRES VECES POR SEMANA PARENTERALMENTE, INTERFERON ALFA 2A PEGILADO, UTILIZANDOSE DE 40 µg A 270 µg ADMINISTRADA UNA VEZ POR SEMANA PARENTERALMENTE ASOCIADO CON ACIDO MICOFENOLICO, UTILIZANDOSE DE 250mg/DIA A 2000mg/DIA ORALMENTE. LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDAD HEPATICA COMO INFECCIONES VIRALES, HEPATITIS CRONICA CIT REFERS TO THE USE OF INTERFERON ALFA 2A, USING 3-6 MILLION IU ADMINISTERED THREE TIMES PER WEEK PARENTERALLY, INTERFERON ALFA 2A PEGILATED, USING 40 µg TO 270 µg ADMINISTERED ONCE A WEEK OF MELTUALLY ASTILIZED ASTILIZED ASTILIZED 250mg. / DAY AT 2000mg / DAY ORALLY. THE COMBINATION MAY BE USEFUL FOR THE TREATMENT OF HEPATIC DISEASE SUCH AS VIRAL INFECTIONS, CHRONIC HEPATITIS C

PE2000000804A 1999-08-13 2000-08-08 MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA PE20010490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
PE20010490A1 true PE20010490A1 (en) 2001-04-27

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000804A PE20010490A1 (en) 1999-08-13 2000-08-08 MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA

Country Status (14)

Country Link
EP (1) EP1220683A2 (en)
JP (1) JP2003507339A (en)
CN (1) CN1368887A (en)
AU (1) AU7408200A (en)
BR (1) BR0013252A (en)
CA (1) CA2380653A1 (en)
HU (1) HUP0202525A3 (en)
MX (1) MXPA02001296A (en)
PE (1) PE20010490A1 (en)
PL (1) PL357367A1 (en)
RU (1) RU2002105485A (en)
TR (1) TR200200401T2 (en)
WO (1) WO2001012214A2 (en)
ZA (1) ZA200200280B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE428714T1 (en) 2004-02-24 2009-05-15 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITORS
ES2349472T3 (en) * 2004-08-12 2011-01-03 Schering Corporation STABLE FORMULATION OF PEGILATED INTERFERON.
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490837A1 (en) 2011-10-21 2014-11-28 Эббви Инк. METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SI3215193T1 (en) * 2014-11-06 2024-02-29 Pharmaessentia Corporation Dosage regimen for pegylated interferon
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
CN1368887A (en) 2002-09-11
CA2380653A1 (en) 2001-02-22
TR200200401T2 (en) 2002-06-21
PL357367A1 (en) 2004-07-26
JP2003507339A (en) 2003-02-25
WO2001012214A2 (en) 2001-02-22
ZA200200280B (en) 2003-04-11
EP1220683A2 (en) 2002-07-10
HUP0202525A2 (en) 2002-11-28
HUP0202525A3 (en) 2003-11-28
WO2001012214A3 (en) 2001-10-04
AU7408200A (en) 2001-03-13
BR0013252A (en) 2002-04-16
RU2002105485A (en) 2004-01-27
MXPA02001296A (en) 2002-07-22

Similar Documents

Publication Publication Date Title
PE20010490A1 (en) MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA
PE20001369A1 (en) COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PEGILADO
PT1265889E (en) MEDICATIONS AGAINST VIRAL PATHOLOGIES
PE119199A1 (en) COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
CL2010000828A1 (en) Pharmaceutical composition comprising a pegylated conjugate of interferon alfa and ribavirin, useful in the preparation of a medicament for chronic hepatitis C infections.
PE72799A1 (en) MODIFIED POLYETHYLENE GLYCOL INTERFERONS
CL2012000420S1 (en) Isoscelic trapezoidal light fixture, triangular, convex and divergent upward major lateral faces; the upper face has an isoscelic trapezoidal recess with beveled edges; the rear face has a "t" projection attached to the cylinder; and the lower face has a wide isoscelic trapezoidal recess, with curved sides.
BR9916027A (en) Glp-1 analogs
BRPI0813237B8 (en) compound, method of preparing the compound, medicine, and use of the compound
MX9202374A (en) 1,3-OXATIOLANES USEFUL IN THE TREATMENT OF HEPATITIS.
ES2183093T3 (en) PREPARATION OF 1,1,1,3,3-PENTACLOROBUTAN AND 1,1,1,3,3-PENTAFLUORBUTAN.
CL2007001752A1 (en) Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
ES2098723T3 (en) BEARING MATERIAL.
AR037910A1 (en) ABSORBENT FOLDABLE ARTICLE
DOP2024000172A (en) ANTIVIRAL COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
BR0307448A (en) Lyophilized preparation comprising immunocytokines
GT198301619A (en) INTERFERON IMMUNE HUMAN HOMOGENEO AND PROCEDURE FOR THE SAME.
PE20001386A1 (en) COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA
AR061352A1 (en) THE USE OF TIMOSINA ALFA 1 TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF MALIGNOM MELANOMA OF STADIUM IV
BR0108997A (en) Adjuvant Immune Therapy for HIV
PE61699A1 (en) PHARMACEUTICAL COMPOSITION OF LAMIVUDINE
CL2008002399A1 (en) Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
ATE124506T1 (en) LARGE WASHER.
PE20010026A1 (en) COMPOSITION INCLUDING INTERFERED ALPHA PEGILADO
CL2024002624A1 (en) Antiviral compounds and methods of their preparation and use

Legal Events

Date Code Title Description
FD Application declared void or lapsed